Skip to main content

Table 1 Clinical trials on MSC application in AKI

From: Novel preconditioning strategies for enhancing the migratory ability of mesenchymal stem cells in acute kidney injury

Aim of study Enrollment Phase Status ClinicalTrials.gov identifier
To determine if the administration of allogeneic MSCs at defined doses is safe in patients who are at high risk of developing significant AKI after undergoing on-pump cardiac surgery 18 Phase I Completed NCT00733876
To determine the safety and efficacy of allogeneic human MSCs in reducing the time to recover from AKI after cardiac surgery 156 Phase II Terminated NCT01602328
To assess the safety and tolerability of SBI-101, a biologic/device combination product using allogeneic human MSCs in subjects with AKI 24 Phase I Recruiting NCT03015623
  1. AKI acute kidney injury, MSC mesenchymal stem cell